Income Statement Cadrenal Therapeutics, Inc.

Stocks

CVKD

US1276362076

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 12:49:47 2026-06-11 pm EDT			5-day change	1st Jan Change
4.070 ^USD	-1.69%		-5.57%	-39.97%

Jun. 03	Cadrenal Therapeutics, Inc. Announces CFO Changes, Effective May 28, 2026	CI
Jun. 03	Cadrenal Therapeutics, Inc. Appoints Quang X. Pham as Interim Principal Accounting Officer, Effective May 28, 2026	CI

53f021012a17bd.TadC0XQHRObdaJzNtSaYws0GgK5fcNlVKdY_8B-9rd0.Cv5vlR9gcqWIEsapglP1jKlEyNk2OLUxeZ4HvSrK3o0Z6SPmHWo-37wirA

Published financial data: CADRENAL THERAPEUTICS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2022	2023	2024	2025
Selling General & Admin Expenses, Total	2.52M	3.55M	6.75M	9.35M
R&D Expenses	429K	4.08M	4.21M	4.1M
Depreciation & Amortization - (IS)	1.38K	1.98K	1.88K	6.87K
Other Operating Expenses, Total	2.95M	7.63M	10.96M	13.46M
Operating Income	-2.95M	-7.63M	-10.96M	-13.46M
Interest Expense, Total	-117K	-17.1K	-	-
Interest And Investment Income	-	249K	309K	224K
Net Interest Expenses	-117K	232K	309K	224K
Other Non Operating Income (Expenses)	-4.26M	-216K	-	-
EBT, Excl. Unusual Items	-7.32M	-7.62M	-10.65M	-13.24M
Other Unusual Items	-	-740K	-	-
EBT, Incl. Unusual Items	-7.32M	-8.36M	-10.65M	-13.24M
Earnings From Continuing Operations	-7.32M	-8.36M	-10.65M	-13.24M
Net Income to Company	-7.32M	-8.36M	-10.65M	-13.24M
Net Income - (IS)	-7.32M	-8.36M	-10.65M	-13.24M
Net Income to Common Incl Extra Items	-7.32M	-8.36M	-10.65M	-13.24M
Net Income to Common Excl. Extra Items	-7.32M	-8.36M	-10.65M	-13.24M
Per Share Items
Net EPS - Basic	-13.92	-9.29	-8.73	-6.64
Basic EPS - Continuing Operations	-13.92	-9.29	-8.73	-6.64
Basic Weighted Average Shares Outstanding	526K	899K	1.22M	1.99M
Net EPS - Diluted	-13.92	-9.29	-8.73	-6.64
Diluted EPS - Continuing Operations	-13.92	-9.29	-8.73	-6.64
Diluted Weighted Average Shares Outstanding	526K	899K	1.22M	1.99M
Normalized Basic EPS	-8.7	-5.29	-5.46	-4.15
Normalized Diluted EPS	-8.7	-5.29	-5.46	-4.15
Supplemental Items
EBITDA	-2.95M	-7.63M	-10.96M	-13.45M
EBITA	-2.95M	-7.63M	-10.96M	-13.46M
EBIT	-2.95M	-7.63M	-10.96M	-13.46M
EBITDAR	-2.7M	-7.6M	-10.93M	-13.43M
Normalized Net Income	-4.58M	-4.76M	-6.66M	-8.27M
Supplemental Operating Expense Items
General and Administrative Expenses	2.52M	3.55M	6.75M	9.35M
Research And Development Expense From Footnotes	429K	4.08M	4.21M	4.1M
Net Rental Expense, Total	4.39K	26.56K	26.56K	26.88K
Imputed Operating Lease Interest Expense	-	10.98K	-	-
Imputed Operating Lease Depreciation	-	15.58K	-	-
Stock-Based Comp., R&D Exp. (Total)	149K	370K	388K	480K
Stock-Based Comp., G&A Exp. (Total)	863K	340K	1.03M	1.46M
Total Stock-Based Compensation	1.01M	710K	1.42M	1.94M

Fiscal Period: December	2022	2023	2024	2025
Assets
Cash And Equivalents	32.59K	8.4M	10.02M	4.01M
Total Cash And Short Term Investments	32.59K	8.4M	10.02M	4.01M
Other Receivables	-	-	38.15K	5.1K
Total Receivables	-	-	38.15K	5.1K
Prepaid Expenses	22.72K	89.67K	42.26K	200K
Other Current Assets, Total	672K	-	14.44K	106K
Total Current Assets	728K	8.49M	10.11M	4.32M
Net Property Plant And Equipment	44.59K	23.28K	6.94K	5.17K
Other Long-Term Assets, Total	5.99K	3.79K	3.79K	2.17K
Total Assets	778K	8.52M	10.12M	4.33M
Liabilities
Accounts Payable, Total	405K	167K	1.5M	651K
Accrued Expenses, Total	864K	638K	1.18M	937K
Short-term Borrowings	43.73K	-	-	-
Current Portion of Leases	22.29K	21.35K	-	-
Total Current Liabilities	1.33M	827K	2.68M	1.59M
Long-Term Debt	553K	-	-	-
Long-Term Leases	21.35K	-	-	-
Other Non Current Liabilities	4.42M	-	-	-
Total Liabilities	6.33M	827K	2.68M	1.59M
Common Stock, Total	8.19K	13.02K	1.78K	2.34K
Additional Paid In Capital	1.15M	22.75M	33.16M	41.7M
Retained Earnings	-6.71M	-15.07M	-25.72M	-38.96M
Total Common Equity	-5.55M	7.69M	7.44M	2.74M
Total Equity	-5.55M	7.69M	7.44M	2.74M
Total Liabilities And Equity	778K	8.52M	10.12M	4.33M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	776K	1.07M	1.88M	2.51M
ECS Total Common Shares Outstanding	546K	868K	1.78M	2.34M
Book Value / Share	-10.16	8.86	4.17	1.17
Tangible Book Value	-5.55M	7.69M	7.44M	2.74M
Tangible Book Value Per Share	-10.16	8.86	4.17	1.17
Total Debt	641K	21.35K	0	0
Net Debt	608K	-8.38M	-10.02M	-4.01M
Debt Equivalent Oper. Leases	-	212K	212K	215K
Account Code - Inventory Valuation	3	3	3	3
Full Time Employees	3	4	4	5

Fiscal Period: December	2022	2023	2024	2025
Net Income	-7.32M	-8.36M	-10.65M	-13.24M
Depreciation & Amortization - CF	1.38K	1.98K	1.88K	6.87K
Depreciation & Amortization, Total	1.38K	1.98K	1.88K	6.87K
Amortization of Deferred Charges, Total - (CF)	73K	13.57K	-	-
Stock-Based Compensation (CF)	1.01M	710K	1.42M	1.94M
Other Operating Activities, Total	4.26M	3.96M	-352	-
Change In Accounts Payable	442K	-238K	1.34M	-852K
Change in Other Net Operating Assets	221K	382K	538K	-459K
Cash from Operations	-1.31M	-3.53M	-7.36M	-12.6M
Capital Expenditure	-2.49K	-3.25K	-6.54K	-5.1K
Cash from Investing	-2.49K	-3.25K	-6.54K	-5.1K
Short Term Debt Issued, Total	220K	-	-	-
Long-Term Debt Issued, Total	1.01M	-	-	-
Total Debt Issued	1.34M	-	-	-
Short Term Debt Repaid, Total	-	-250K	-	-
Total Debt Repaid	-	-250K	-	-
Issuance of Common Stock	8.67K	12.15M	5.14M	7.16M
Other Financing Activities, Total	-	-	3.84M	-563K
Cash from Financing	1.35M	11.9M	8.98M	6.6M
Net Change in Cash	35.55K	8.37M	1.62M	-6.01M
Supplemental Items
Levered Free Cash Flow	-	-3.92M	-3.56M	-7.78M
Unlevered Free Cash Flow	-	-3.92M	-3.56M	-7.78M
Change In Net Working Capital	-	-142K	-1.87M	1.31M
Net Debt Issued / Repaid	1.34M	-250K	-	-

Fiscal Period: December	2022	2023	2024	2025
Profitability
Return on Assets	-	-102.62	-73.49	-116.44
Return on Total Capital	-	-340.35	-90.41	-165.32
Return On Equity %	-	-780.59	-140.78	-260.11
Return on Common Equity	-	-780.59	-140.78	-260.11
Short Term Liquidity
Current Ratio	0.55	10.27	3.77	2.72
Quick Ratio	0.02	10.16	3.75	2.53
Operating Cash Flow to Current Liabilities	-0.98	-4.27	-2.74	-7.94
Long Term Solvency
Total Debt/Equity	-11.54	0.28	-	-
Total Debt / Total Capital	-13.05	0.28	-	-
LT Debt/Equity	-10.35	-	-	-
Long-Term Debt / Total Capital	-11.7	-	-	-
Total Liabilities / Total Assets	813.36	9.71	26.51	36.7
EBIT / Interest Expense	-25.22	-446.34	-	-
EBITDA / Interest Expense	-25.21	-444.67	-	-
(EBITDA - Capex) / Interest Expense	-25.23	-444.86	-	-
Total Debt / EBITDA	-0.22	-0	-	-
Net Debt / EBITDA	-0.21	1.1	0.91	0.3
Total Debt / (EBITDA - Capex)	-0.22	-0	-	-
Net Debt / (EBITDA - Capex)	-0.21	1.1	0.91	0.3
Growth Over Prior Year
EBITDA, 1 Yr. Growth %	-	159.04	43.61	22.77
EBITA, 1 Yr. Growth %	-	158.98	43.6	22.81
EBIT, 1 Yr. Growth %	-	158.98	43.6	22.81
Earnings From Cont. Operations, 1 Yr. Growth %	-	14.09	27.45	24.28
Net Income, 1 Yr. Growth %	-	14.09	27.45	24.28
Normalized Net Income, 1 Yr. Growth %	-	3.99	39.84	24.28
Diluted EPS Before Extra, 1 Yr. Growth %	-	-33.27	-6	-23.98
Net Property, Plant and Equip., 1 Yr. Growth %	-	-47.78	-70.18	-25.49
Total Assets, 1 Yr. Growth %	-	994.77	18.83	-57.26
Tangible Book Value, 1 Yr. Growth %	-	-238.57	-3.29	-63.19
Common Equity, 1 Yr. Growth %	-	-238.57	-3.29	-63.19
Cash From Operations, 1 Yr. Growth %	-	168.61	108.41	71.28
Capital Expenditures, 1 Yr. Growth %	-	30.89	100.89	-21.92
Levered Free Cash Flow, 1 Yr. Growth %	-	-	-9.02	118.49
Unlevered Free Cash Flow, 1 Yr. Growth %	-	-	-9.09	118.49
Compound Annual Growth Rate Over Two Years
EBITDA, 2 Yr. CAGR %	-	-	92.87	32.78
EBITA, 2 Yr. CAGR %	-	-	92.85	32.8
EBIT, 2 Yr. CAGR %	-	-	92.85	32.8
Earnings From Cont. Operations, 2 Yr. CAGR %	-	-	20.59	25.86
Net Income, 2 Yr. CAGR %	-	-	20.59	25.86
Normalized Net Income, 2 Yr. CAGR %	-	-	20.59	31.83
Diluted EPS Before Extra, 2 Yr. CAGR %	-	-	-20.8	-15.47
Net Property, Plant and Equip., 2 Yr. CAGR %	-	-	-60.54	-52.86
Total Assets, 2 Yr. CAGR %	-	-	260.68	-28.73
Tangible Book Value, 2 Yr. CAGR %	-	-	15.77	-40.33
Common Equity, 2 Yr. CAGR %	-	-	15.77	-40.33
Cash From Operations, 2 Yr. CAGR %	-	-	136.6	88.93
Capital Expenditures, 2 Yr. CAGR %	-	-	62.16	25.24
Levered Free Cash Flow, 2 Yr. CAGR %	-	-	-	40.99
Unlevered Free Cash Flow, 2 Yr. CAGR %	-	-	-	40.94
Compound Annual Growth Rate Over Three Years
EBITDA, 3 Yr. CAGR %	-	-	-	65.91
EBITA, 3 Yr. CAGR %	-	-	-	65.92
EBIT, 3 Yr. CAGR %	-	-	-	65.92
Earnings From Cont. Operations, 3 Yr. CAGR %	-	-	-	21.81
Net Income, 3 Yr. CAGR %	-	-	-	21.81
Normalized Net Income, 3 Yr. CAGR %	-	-	-	21.81
Diluted EPS Before Extra, 3 Yr. CAGR %	-	-	-	-21.88
Net Property, Plant and Equip., 3 Yr. CAGR %	-	-	-	-51.23
Total Assets, 3 Yr. CAGR %	-	-	-	77.16
Tangible Book Value, 3 Yr. CAGR %	-	-	-	-20.98
Common Equity, 3 Yr. CAGR %	-	-	-	-20.98
Cash From Operations, 3 Yr. CAGR %	-	-	-	112.44
Capital Expenditures, 3 Yr. CAGR %	-	-	-	27.1